Stocks / Stock overview

Solstice Advanced Materials Inc. (SOLS)

$56.16-0.81%Aft $57.00 (+1.50%)Market cap $8.92B

NasdaqGS · Price as of · Nasdaq Real Time Price

Stock Scorer
Scoring…
Analyst consensus
Buy$80.43
  • Analysts7
  • Implied upside+43.2%
  • Target range$70.00 to $95.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
Next earnings
October 29, 2026date estimated
  • EPS expected$0.71
  • Revenue expected$1.02B +5.1%
  • Estimate range$0.68 to $0.72
Consensus of 6 analysts for the quarter ending September 30, 2026. Estimates are what Wall Street expects, not our forecast.
Source: Yahoo Finance earnings calendar

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
425August 11, 2026425
4August 4, 2026FORM 4
4August 3, 2026FORM 4
4August 3, 2026FORM 4
4August 3, 2026FORM 4
425August 3, 2026425
4July 30, 2026FORM 4
4July 30, 2026FORM 4
All SEC filings

Frequently asked questions

When does SOLS report earnings?

Solstice Advanced Materials Inc. (SOLS) is scheduled to report quarterly results on October 29, 2026 (estimated). The 6-analyst consensus is $0.71 per share on revenue of $1.02B for the quarter ending September 30, 2026. The date is an estimate from past reporting patterns and can move until the company confirms it.

What do analysts expect for SOLS?

7 analysts cover Solstice Advanced Materials Inc. (SOLS). The consensus rating is Buy. The average price target is $80.43, in a range of $70.00 to $95.00.

Are insiders buying or selling SOLS?

We have no qualifying Form 4 insider purchases or sales on record for Solstice Advanced Materials Inc. (SOLS). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Where can I see SOLS SEC filings?

Recent filings are listed on this page, newest first. The latest is a 425 filed August 11, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.